DCISionRT Test Appears Predictive of Benefit From Radiation Therapy DCIS of the Breast


Findings from the SqeDCIS trial indicated that DCISionRT was predictive of radiotherapy benefit in patients with ductal carcinoma in situ of the breast.

Testing with DCISionRT appeared to predict the benefit of radiation in reducing 10-year local invasive breast cancer risk in patients with ductal carcinoma in situ (DCIS) of the breast, according to a press release for the randomized SqeDCIS trial.1

The trial enrolled a total of 504 patients who had complete data and negative surgical margins. DCISionRT divided patients into either the elevated- (52%) or low-risk groups (48%).2 Patients with elevated-risk achieved a significantly decreased relative 10-year ipsilateral total recurrence (TotBE; HR, 0.32) and 10-year ipsilateral invasive recurrence (InvBE; HR, 0.24) rates following treatment with radio therapy. This translated to absolute decreases of 15.5% and 9.3% in each group, respectively. Notably, no significant risk differences were observed in the low-risk group following treatment with radiotherapy.

Investigators noted that findings from the trial are consistent with 3 previous studies assessing DCISionRT, which served to further validate the test as a potential strategy.

“In this study, DCISionRT demonstrated statistically significant radiation therapy benefit in patients with higher Decision Scores (DS), and minimal benefit in lower scores," principal investigator, Fredrik Wärnberg, MD, PhD, a professor in the Department of Surgery at the Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden, said in a press release. “This was a highly valuable use of bio-banked tissue from the landmark SweDCIS patient cohort as no other randomized studies have been able to identify DCIS patients who can omit RT.”

Additional findings from the study indicated that, when using a cut off of DS more than 3.0, the test did not appear to be predictive of a benefit from radiotherapy (P = .093). However, investigators noted that using a cut off of 2.8 revealed that radiotherapy benefit was higher in terms of InvBE interaction (P = .038). Per the DS 5 units, 10-year recurrence without radiotherapy was found to significantly increase (TotBE: HR, 1.5; InvBE: HR, 1.5). Moreover, continuous DS was found to be prognostic of TotBE risk, however categorical DS did not reach significance.

“We are thrilled to publish this latest data on DCISionRT, the only DCIS test validated with peer-reviewed published level 1b clinical evidence. The results confirm the power of the DCISionRT assay to predict radiotherapy benefit and enabling personalized treatment decisions,” Dan Forche, president and chief executive officer at PreludeDx, said in a press release. "The consistency of results with prior validation studies substantiates the robustness and reliable performance of DCISionRT. We believe these much-anticipated results will have a significant impact on clinical practice for DCIS patient management.”


  1. PreludeDx™ DCISionRT® predicts radiation benefit in landmark randomized SweDCIS clinical trial. News release. PreludeDx. December 7, 2021. Accessed December 9, 2021. https://prn.to/31IVD6f
  2. Wärnberg F, Karlsson P, Holmberg E, et al. Prognostic risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (DCIS) of the breast, in a randomized clinical trial (SweDCIS). Cancers. 2021;13(23):6103. doi:10.3390/cancers13236103
Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content